Abstract
NSAIDs are widely used all over the world. NSAID use is rising due to increasing availability without a prescription, use of aspirin for prevention of thrombotic disorders and the ageing population. Aspirin is used as an analgesic drug in many countries, but the main current indication is low-dose aspirin for the prevention of cardiovascular events. However, NSAIDs and aspirin use account for approximately 20-25% of all reported drug adverse events. Most of those are gastrointestinal including dyspepsia, hemorrhage, perforation and even death. The COX-2- selective inhibitors (coxibs) have demonstrated equivalent efficacy to nonspecific NSAIDs in the management of arthritis and pain but have less gastrointestinal adverse events, although coxibs and probably all NSAIDs, significantly increase risk of serious thromboembolic events. Concomitant use of low-dose aspirin is present in more than 20% of all patients taking either NSAIDs or coxibs, thus increasing the risk of gastrointestinal side effects. Furthermore, at present, it is not known whether aspirin decreases the cardiovascular risks of COX-2 inhibitors or NSAIDs. Appropriate strategies for gastrointestinal risk reduction with NSAIDs and aspirin must consider the overall health status of our patients including the presence of cardiovascular and gastrointestinal risk factors. Use of the lowest possible dose of these drugs, gastroprotectants, especially proton pump inhibitors and Helicobacter pylori eradication will reduce the risk of gastrointestinal side effects in patients taking low-dose aspirin and NSAIDs or coxibs
Keywords: Aspirin, low dose aspirin, NSAIDs, COX-inhibitors, coxib, Helicobacter pylori, gastrointestinal events, cardiovascular events
Current Pharmaceutical Design
Title: How to Advise Aspirin Use in Patients Who Need NSAIDs
Volume: 13 Issue: 22
Author(s): F. Sopena and A. Lanas
Affiliation:
Keywords: Aspirin, low dose aspirin, NSAIDs, COX-inhibitors, coxib, Helicobacter pylori, gastrointestinal events, cardiovascular events
Abstract: NSAIDs are widely used all over the world. NSAID use is rising due to increasing availability without a prescription, use of aspirin for prevention of thrombotic disorders and the ageing population. Aspirin is used as an analgesic drug in many countries, but the main current indication is low-dose aspirin for the prevention of cardiovascular events. However, NSAIDs and aspirin use account for approximately 20-25% of all reported drug adverse events. Most of those are gastrointestinal including dyspepsia, hemorrhage, perforation and even death. The COX-2- selective inhibitors (coxibs) have demonstrated equivalent efficacy to nonspecific NSAIDs in the management of arthritis and pain but have less gastrointestinal adverse events, although coxibs and probably all NSAIDs, significantly increase risk of serious thromboembolic events. Concomitant use of low-dose aspirin is present in more than 20% of all patients taking either NSAIDs or coxibs, thus increasing the risk of gastrointestinal side effects. Furthermore, at present, it is not known whether aspirin decreases the cardiovascular risks of COX-2 inhibitors or NSAIDs. Appropriate strategies for gastrointestinal risk reduction with NSAIDs and aspirin must consider the overall health status of our patients including the presence of cardiovascular and gastrointestinal risk factors. Use of the lowest possible dose of these drugs, gastroprotectants, especially proton pump inhibitors and Helicobacter pylori eradication will reduce the risk of gastrointestinal side effects in patients taking low-dose aspirin and NSAIDs or coxibs
Export Options
About this article
Cite this article as:
F. Sopena and A. Lanas , How to Advise Aspirin Use in Patients Who Need NSAIDs, Current Pharmaceutical Design 2007; 13 (22) . https://dx.doi.org/10.2174/138161207781368837
DOI https://dx.doi.org/10.2174/138161207781368837 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Strategies for Salt Reduction in Foods
Recent Patents on Food, Nutrition & Agriculture Correlations Between Carotid IMT, Factor VIII Activity Level and Metabolic Disturbances: A Cardio-Vascular Risk Factor in the HIV Positive Persons
Current HIV Research Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Therapeutic Approaches in the Stimulation of the Coronary Collateral Circulation
Current Cardiology Reviews Microbial Metabolomics
Current Genomics Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design An Augmented Passive Immune Therapy to Treat Fulminant Bacterial Infections
Recent Patents on Anti-Infective Drug Discovery Silicon in Plant Tolerance Against Environmental Stressors: Towards Crop Improvement Using Omics Approaches
Current Proteomics Pro-Angiogenic Effect of Endomyocardial Biopsy-Derived Cells for Cardiac Regeneration
Current Tissue Engineering (Discontinued) Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Depression, Serotonin and Tryptophan
Current Pharmaceutical Design Association of Common Variants in the IL-33/ST2 Axis with Ischemic Stroke
Current Neurovascular Research Structural Neuroimaging Findings in Major Depressive Disorder Throughout Aging: A Critical Systematic Review of Prospective Studies
CNS & Neurological Disorders - Drug Targets Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets HDL as a Target for Glycemic Control
Current Drug Targets